Up-to-date, authoritative and comprehensive, Heart Failure, 4th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald's Heart Disease helps you make the most of new drug therapies such as angiotensin receptor neprilysin inhibitors (ARNIs), recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Dr. G. Michael Felker and Dr. Douglas Mann, this outstanding reference gives health care providers the knowledge to improve clinical outcomes in heart failure patients. Focuses on a clinical approach to treating heart failure, resulting from a broad variety of cardiovascular problems. Covers the most recent guidelines and protocols, including significant new updates to ACC, AHA, and HFSA guidelines. Covers key topics such as biomarkers and precision medicine in heart failure and new data on angiotensin receptor neprilysin inhibitors (ARNIs). Contains four new chapters: Natriuretic Peptides in Heart Failure; Amyloidosis as a Cause of Heart Failure; HIV and Heart Failure; and Neuromodulation in Heart Failure. Covers the pathophysiological basis for the development and progression of heart failure. Serves as a definitive resource to prepare for the ABIM's Heart Failure board exam. 2016 British Medical Association Award: First Prize, Cardiology (3rd Edition). Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
Heart Failure: A Companion to Braunwald's Heart Disease, Fourth Edition Contents Section 1 Basic Mechanisms of Heart Failure 1. Molecular Basis for Heart Failure 2. Cellular Basis for Heart Failure 3. Cellular Basis for Myocardial Regeneration and Repair 4. Myocardial Basis for Heart Failure: Role of Cardiac Interstitium Section 2 Mechanisms of Disease Progression in Heart Failure 5. Molecular Signaling Mechanisms of the Renin-Angiotensin System in Heart Failure 6. Adrenergic Receptor Signaling in Heart Failure 7. Role of Innate Immunity in Heart Failure 8. Oxidative Stress in Heart Failure 9. Natriuretic Peptides in HF 10. Systolic Dysfunction in Heart Failure 11. Alterations in Ventricular Function: Diastolic Heart Failure 12. Alterations in Ventricular Structure: Role of Left Ventricular Remodeling and Reverse Remodeling in Heart Failure 13. Alterations in the Sympathetic and Parasympathetic Nervous Systems in Heart Failure 14. Alterations in the Peripheral Circulation in Heart Failure 15. Alterations in Kidney Function Associated with Heart Failure 16. Alterations in Skeletal Muscle in Heart Failure 17. Alterations in Cardiac Metabolism Section 3 Etiological Basis for Heart Failure 18. Epidemiology of Heart Failure 19. Heart Failure as a Consequence of Ischemic Heart Disease 20. Heart Failure as a Consequence of Dilated Cardiomyopathy 21. The Restrictive and Infiltrative Cardiomyopathies and Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy 22. Cardiac Amyloidosis 23. Heart Failure as a Consequence of Hypertrophic Cardiomyopathy 24. Heart Failure as a Consequence of Genetic Cardiomyopathy 25. Heart Failure as a Consequence of Hypertension 26. Heart Failure as a Consequence of Valvular Heart Disease 27. Heart Failure as a Consequence of Congenital Heart Disease 28. Heart Failure as a Consequence of Viral and Nonviral Myocarditis 29. Heart Failure in the Developing World 30. Heart Failure and Human Immunodeficiency Virus Section 4 Clinical Assessment of Heart Failure 31. Clinical Evaluation of Heart Failure 32. Cardiac Imaging in Heart Failure 33. Biomarkers and Precision Medicine in Heart Failure 34. Hemodynamics in Heart Failure Section 5 Therapy for Heart Failure 35. Disease Prevention in Heart Failure 36. Management of Acute Decompensated Heart Failure Guidelines 37. Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction Guidelines: Management of Heart Failure with a Reduced Ejection Fraction 38. Management of Arrhythmias and Device Therapy in Heart Failure Guidelines 39. Treatment of Heart Failure with Preserved Ejection Fraction Guidelines 40. Management of Heart Failure in Special Populations: Older Patients, Women, and Racial/Ethnic Minority Groups 41. Gene and Stem-Cell Based Therapies in Heart Failure 42. Neuromodulation in Heart Failure 43. Pulmonary Hypertension 44. Cardiac Transplantation 45. Circulatory Assist Devices in Heart Failure 46. Cardio-Oncology and Heart Failure 47. Disease Management and Telemedicine in Heart Failure 48. Management of Comorbidities in Heart Failure 49. Quality and Outcomes in Heart Failure 50. Decision Making and Palliative Care in Advanced Heart Failure